Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 19:20:35 16/07/2024 BST			5-day change	1st Jan Change
150.2 ^USD	+0.64%		+2.36%	-3.97%

11:14am	EQT Unit Invests in Biotechnology Company Asceneuron	MT
07-15	Equity Markets Higher After Fed Chair Powell's Comments	MT

Johnson & Johnson to Participate in the TD Cowen 44th Annual Health Care Conference

January 31, 2024 at 12:24 pm

New Brunswick - Johnson & Johnson (NYSE: JNJ) will participate in the TD Cowen 44th Annual Health Care Conference on Monday, March 4th, at the Boston Marriott Copley Place, Boston, MA.

Hani Abouhalka, Company Group Chairman, Surgery, Johnson & Johnson MedTech will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.

Contact:

Email: media-relations@its.jnj.com

Email: investor-relations@its.jnj.com

Latest news about Johnson & Johnson

EQT Unit Invests in Biotechnology Company Asceneuron	10:14am	MT
Equity Markets Higher After Fed Chair Powell's Comments	07-15	MT
Equity Markets Rise Intraday After Fed Chair Powell's Comments	07-15	MT
Stocks Gain Pre-Bell Ahead of Key Earnings; Asia Mixed, Europe Down	07-15	MT
Brace for a flurry of speeches from Fed officials	07-15
Certain Common Stock of Kenvue Inc. are subject to a Lock-Up Agreement Ending on 14-JUL-2024.	07-13	CI
J&J: completes acquisition of Yellow Jersey for $1.25 billion	07-12	CF
Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeutics	07-11	MT
Mixed feelings	07-09
Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing	07-09	MT
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9)	07-09	RE
Emergent, J&J settle COVID vaccine supply deal dispute	07-08	RE
Emergent Biosolutions to Get $50 Million from Covid-19 Manufacturing Settlement with Johnson & Johnson Unit	07-08	DJ
J&J to pay $50 million to Emergent to resolve manufacturing deal for COVID vaccine	07-08	RE
The battle over J&J's bankruptcy plan to end talc lawsuits	07-08	RE
Stryker Corporation : Major Player in Medical Devices	07-05
Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	07-03	MT
Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	07-03	DJ
J&J: full approval for Sirturo in tuberculosis	07-03	CF
J&J: promising results in multiple myeloma	07-02	CF
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	07-02	MT
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	07-02	CI
Momentum Picks Q3 2024: 5 stocks for the summer	07-01
New semester, new state of mind	07-01
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	06-28	MT

Chart Johnson & Johnson

Duration

Period

More charts

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).

Sector

Pharmaceuticals

Calendar

17/07/2024 - Q2 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm

More Strategies

Ratings for Johnson & Johnson

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

149.2 USD

Average target price

171.5 USD

Spread / Average Target

+14.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOHNSON & JOHNSON	-3.97%	359B
ELI LILLY AND COMPANY	+62.30%	856B
NOVO NORDISK A/S	+38.95%	631B
MERCK & CO., INC.	+15.76%	325B
ABBVIE INC.	+8.89%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+16.03%	177B
PFIZER, INC.	+2.17%	165B
SANOFI	+2.41%	126B

Other Pharmaceuticals

Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Johnson & Johnson to Participate in the TD Cowen 44th Annual Health Care Conference

EPS Revisions